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 1   INTRODUCTION 
 
 
 
Anti-cholinestrase  drugs  like  neostigmine  are  given  at  the  end  of  surgical 
procedures to accelerate recovery from residual neuromuscular blockade 
produced by non-depolarising neuromuscular blocking drugs. 
 
When  atracurium  is  used  as  muscle  relaxant  which  has  a  novel  
mechanism of  excretion  which  does  not  depend  either  on  renal  or  hepatic  
function. The atracurium induced muscle relaxation can recover spontaneously 
but slowly. Anti- cholinesterase  is  needed  just  to  speed  up  recovery  from 
residual  blockade . 
 
Since  the  reversal  agent  like  neostigmine  has  its  own  drawbacks  of  
muscarinic  side  effects  of  bradycardia , hypotension , increased  glandular 
secretions  . The  dose  of  neostigmine  reduction  might  help  in  reducing these  
side-effects  without  affecting  its  purpose  of  reversing  the  residual 
neuromuscular  blockade . 
 
In  addition  use  of  neuromuscular  monitor , helps  us  to  objectively  judge The  
recovery  of  the  neuromuscular  junction  , from  residual  non – depolarizing   
blockade  when  used  in  addition  to  the  clinical  signs  of  recovery of   muscle  
power  . 
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2   AIM OF THE STUDY 
 
 
To   study  and   compare  three  different  doses  of  neostigmine  as  reversal 
agent  to  residual  neuromuscular  blockade  of  atracurium . 
 
 
1.  On  recovery  of  residual  neuromuscular  blockade  produced  by  atracurium  
(intubating  dose  of  0.5 mg / kg  ,top-up  dose  of  0.15 mg / kg ) 
 
2.  On the haemo- dynamic   changes. 
 
3.    On the adverse side effects. 
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3 PHYSIOLOGY OF NEUROMUSCULAR JUNCTION 
 
 Neuromuscular  junction  (NMJ)  is  a  synapse  at  which  an  electrical  impulse 
traveling  down  a  nerve  is  converted  into  muscle  action  potential  and 
contraction  by  chemical  transmitters . A  motor  neuron  along  with  all  the 
muscle  fibers  supplied  by  it  forms  a  motor  unit , which  follows  all  or  none 
law  of  contraction. 
 
PARTS   OF NEUROMUSCULAR   JUNCTION 
 
To  understand   the  physiological events  occurring  during neuromuscular 
transmission,  it  is  essential  to  understand  the  anatomy  of  NMJ , which  can 
be  divided  into  
 
1. Presynaptic nerve terminal 
 
2. Synaptic cleft 
 
3. Post synaptic membrane acetylcholine receptors 
 
4. Contractile apparatus 
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PRESYNAPTIC    NERVE   TERMINAL 
 
Presynaptic  nerve  terminal  contains  all  the  apparatus  necessary  for  the  
synthesis of   acetylcholine , which  exist  in  two  forms :  20%  in  the  soluble  
form  in  the axoplasm  and  80%  in  vesicles , which  can  be  further  divided  
into  a  readily available  pool  and  a  reservoir  pool . The  vesicles  are  40 – 50  
nm  in  diameter  each  containing  1000 – 10000  molecules  of  Ach . The  walls  
of  the  vesicles  contains  synapsins  that  help  in  anchoring  the  vesicles  to 
the  cytoskelatal  framework  of  the  axoplasm . 
 
At  the  membrane  facing  the  synaptic  cleft ,  there  is  an  electron  dense  
patch, the  active  zone ,  around  which  the  readily  available  pool  of            
Ach vesicles  arranged Electron  microscopy  shows  small  pores  between  the  
vesicles  at  the  active  zone. These are the calcium channels. The terminal also 
contains sodium and potassium channels. 
 
The  nerve  endings  on  fast  muscles  are  longer  and  more  complicated  than  
those  on  slow  muscles . The reason for this is unclear. These  differences  in  
the  nerve endings  on  the  muscle  surfaces  may  play  a  role  in  the  
differences  in  the  response to  muscle  relaxants  of  fast  and  slow  muscles .  
 
 5 
 
 
 
 
 
SYNAPTIC    CLEFT: 
 
It  is  20  nm  wide  space  between  the  nerve  terminal  and  the  muscle  end  
plate . The  nerve  and  the  muscles  are  held  in  tight  alignment  by  protein  
filaments  ,which  span  the  cleft  between  nerve  and  end plate  . The  muscle  
surface  is  heavily corrugated  with  deep  invaginations  of  the  junctional  cleft  ,  
the  primary  clefts and   the  secondary  clefts ,  between  the  folds  in  muscle  
membrane  . The  shoulders of  the  folds  are  densely  populated  with  
acetylcholine  receptors  about  5  million  of  them  in  each   junction. These 
receptors are spare in the depths between the folds. Instead these deep areas 
contain sodium channels. These  sodium  channels  have two  component  gates 
, voltage  and  time  dependant  gates . 
POST SYNAPTIC   MEMBRANE – Ach   RECEPTORS: 
 
The  Ach  receptors  at  the  NMJ  are  nicotinic  and  can  be  divided  into  
presynaptic and  postsynaptic . The latter are further divided into junctional and 
extrajunctional. The Ach receptor is a pentameric transmembrane spanning 
protein.  The  5  protein subunits  are  arranged  in  the  form  of   a  rosette  with  
a  central ion channel. The molecular weight   of the receptor is 250 000 - 270 
000. The junctional receptor contains  2α , β , δ  and  ε . The  extrajunctional  
receptor  contains  2α , β , δ  and  γ which  proliferate  in  abnormal  conditions . 
These  extra cellular  surface  of  the  alpha  subunits  contains  high  affinity  Ach  
binding  sites.     
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CONTRACTILE    APPARATUS: 
 
The  contractile  apparatus   of  the  muscle  is  formed  by  the  myofilament  
comprising the  thin  actin  filaments  and  thick  myosin  filaments ,  along  with  
tropomyosin, troponin I, T  and  C . Tropomyosin  is  attached  to  the  myosin  
binding  site  of  actin. The myofilaments combine to form myofibrils. The  muscle  
plasma  membrane ,  the sarcolemma   invaginates  to  form  T-tubules  which  
lies  in  close  association  with sarcoplasmic  reticulam  which  is  a  collection  of  
sacs  and  tubules  acting  as   a  reservoir  for  calcium . 
MECHANISM   OF   NEUROMUSCULAR   TRANSMISSION 
MECHANISM OF Ach RELEASE: 
 
An  action  potential  traveling  down  the  nerve  causes  the  sodium  channels  
in  the presynaptic  nerve  terminal  to  open  , leading  to  sodium  influx  .The  
change  in voltage  produced  by  such  an  influx  activates  the  calcium  
channels  , which  open  up  leading  to  calcium  entry . Calcium  mediated  
activation  of  calcium  calmodulin dependent    protein  kinases  leads  to  
phosphorylation  of  synapsins  in  the   vesicle wall,  causing  the  vesicles  to  
break  away  from  the  cytoskeletal  framework . The vesicles  then  attaches  to  
the  active  zones  with  release  of  Ach  molecules .  Each nerve  impulse  
causes  the  release  of  around  100 - 400  quanta  of  Ach .  Activation  of  
around  20 – 25 %  receptors  is  essential  for  impulse  transmission . 
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BINDING   OF Ach   TO RECEPTOR: 
 
The  Ach  molecule  released  into  the  synaptic  cleft  binds  to  the  alpha  
subunit. binding  of  Ach  to  both  the alpha  subunits  activates  the  receptor ,  
leading  to configurational  changes  in  the  receptor  structure  and  opening  up  
of  ion  channels .  
 
This  leads  to  depolarization  of  the  muscle  end  plate  which  when  of  a  
sufficient magnitude  causes  a  wave  of   depolarization  to  spread  across  the  
muscle sarcolemma  by  means  of   activation  of  the  voltage  dependent  gates  
of  the  sodium channels  in  the   perijunctional   zones  .  This   depolarization   
wave   moving   down the    T – tubule causes release of calcium from 
sarcoplasmic reticulam. Calcium  so released   binds   to   troponin   C   causing   
tropomyosin   to   move   and   expose   the  myosin  binding  sites  of  action  
leading  to  the  formation  of  cross  linkage  of  actin and  myosin  heads .They  
slide  over  each  other  leading  to  shortening  of    the myofilaments and  
muscle  contraction . 
 
DISSOCIATION   OF Ach FROM   RECEPTOR: 
 
The  Ach  molecule  remain  attached  to  its  receptor  for  a  very  short  period  
of  less than  1  millisecond,  after  which  it  dissociates  from  the  receptor  and  
is  hydrolysed by  the  enzyme  acetylcholinestrase.  It  hydrolyses  Ach into  
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acetate  and  choline ,  the choline  being  taken  up  by  the  presynaptic  nerve  
terminal  and  used  for  further  Ach  synthesis . 
MECHANISM   OF   NON – DEPOLARISING   BLOCKADE: 
 
Non – depolarizing  muscle relaxant are drugs having an  affinity for the alpha 
subunits of   the  acetylcholine  receptors  mainly  at  the  postjunctional  nicotinic  
receptors  and also  at  the  prejunctional  sites  of  nerve  endings .  Binding  of  
these  relaxants  to  the alpha  subunits  of  a  Ach  receptor  cannot  open  the  
ion  channel  and  it  also  prevent further  binding  of  Ach  molecule .  So  an  
action  potential  is  not  developed  and there  is  no  contraction  of  muscle  fibre 
.This  competitive  blockade  of  Ach  receptor is  termed  as  non – depolarizing  
blockade. 
 
MARGIN   OF   SAFETY: 
 
Atleast  75 %  of  receptors  must  be  occupied  before  neuromuscular  
transmission  is impaired  and  if  more  90 %  of  the  receptors  are occupied ,  
transmission   fails. 
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CHARACTERISTIC    FEATURES: 
1.  Slow onset to maximal effect and slow recovery compared to succinylcholine 
 
2.  The  central   muscles  like  the  diaphragm ,  larynx ,  masseter ,  orbicularis  
oculi tend   to  be  affected  earlier  and  recover  sooner  than  those  of  the  
peripheral [adductorpollicis] probably as a result of preferential perfusion. 
 
3.  Presence of fade and post- tetanic potentiation. 
 
4.  Despite  flaccid  paralysis , the  muscles  are  still  able  to  respond  to  direct 
stimulation. 
 
5.  The muscle block is reversed pharmacologically by anticholinestrase drugs. 
 
MECHANISM   OF   DEPOLARISING   N M J   BLOCKADE : 
 
 Depolarising  agents  like  suxamethonium  cause  initial  depolarization  of  
endplate due  to   acetylcholine  like  actions ,  which  is  transduced   into  muscle  
contraction ,    but  repeated  action  on  the  receptor   leads  to  a  persistent  
depolarizing  voltage . This  influences  the  sodium  channels  in  the  vicinity  of  
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the  endplate ,  the     perijunctional  area ,  where  the  transmembrane  voltage  
causes  the  voltage  gates  to   remain  open  and  the  time  gates  to  remain  
closed ,  thereby  preventing  further  ion  entry  through  the  channel . Further  
spread  of   the  depolarization   is  arrested ,  and   it  remains  confined  to  the  
endplate  only .  With  the  progress  of  depolarization  arrested ,  the  channels  
in  the  remainder  of  the  muscle  are  freed  of  the  depolarizing  influence  and  
return  to  their  resting  state . Thus 3 discrete zones can be delineated namely 
 
1. Endplate – persistently depolarized. 
2. Perijunctional  area – sodium  channels  still  under  the  depolarizing  influence   
are frozen  in  closed  state . 
3. Rest  of  the  muscle – relaxed ,  as  sodium  channels  return  to  resting  state 
. 
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4 PHARMACOLOGY 
 
                                                          
NEOSTIGMINE: 
 
 
 
MECHANISM   OF   ACTION: 
 
It  produces  reversible  inhibition  of  acetylcholinestrase  by  formation  of  a  
carbamyl ester  complex  at  the  esteratic  site  of  the  enzyme .  Carbamylated 
acetylcholinestrase has a half – time of about 15 to 30 minutes. This 
carbamylated   acetylcholinestrase cannot hydrolyse acetylcholine until the 
carbamate – enzyme bond dissociates. 
 
STRUCTURE   ACTIVITY   RELATIONSHIP: 
 
Acetylcholinestrase  consist  of  an  anionic  and  an  esteratic  site  that  are  so  
arranged that  they  are  complimentary   to  the  natural  substrate  acetylcholine 
. The  anionic  site  of  the  enzyme  binds  the  quaternary  nitrogen  of  
acetylcholine . This  binding serves  to  orient  the  ester  linkage  of  acetylcholine  
to  the  esteratic  site  of acetylcholinestrase .  
 
Neostigmine   is  a  quaternary  ammonium  derivative  of  physostigmine ,  
having  a greater  stability   and  equal  or  greater  potency . 
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PHARMACOKINETICS: 
Elimination half   time:  7 7 minutes. 
Volume of distribution:  0 .7 L / Kg. 
Clearance:  9.2 ml / kg / min. 
Renal  contribution  to  total  clearance [ % ]  :  54  % . 
Speed of onset:  Intermediate. 
Duration:  54 minutes. 
Principle site of action:  postsynaptic. 
Anticholinergic dose: 20 microgram / kg 
Lipid solubility:  Poorly lipid soluble. 
Onset of action:  7 to 11 min. 
 
Metabolism: hepatic metabolism - 50 %. Principle  metabolite -  3 – hydroxyl –
phenyl  -  trimethylammonium , which  has  1 / 10  th  the  antagonist  activity  of  
the parent   compound . 
 
Influence  of  patient  age :  dose  required  to  produce  equivalent  effect  is  less  
in infants  and  children  than  in  adults . Duration  of  maximum  response  
produced  by  neostigmine  is  prolonged  in  elderly  compared  with  younger  
patients reflecting   a  smaller  extra – cellular  fluid  volume  and  slowed  rate  of  
plasma clearance  in elderly  patients. 
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PHARMACOLOGICAL    EFFECTS: 
                               
Reflects  the  accumulation  of  acetylcholine  at  muscarinic  and  nicotinic 
cholinergic  receptor  sites . 
 
Cardio – vascular system:  
 
Bradycardia  and  /  or  bradydysrythmias  such  as  nodal  and  ventricular  
escape beats  and  asytole . It   reflects  slowing  of  the  conduction  of  cardiac  
impulse through  the  atrio – ventricular  node . Decrease  of  systemic  blood  
pressure  probably  reflects  decrease  in  systemic  vascular  resistance , 
although  the  coronary  and  pulmonary  circulations  may  manifest  an  opposite  
response . 
 
Gastro-intestinal tract: 
 
Enhance  gastric  fluid  secretion  by  parietal  cells  and  increase  the  motility  of  
the  entire  G.I.T., particularly  large  intestine  reflecting  the  effects  of 
accumulated  Ach  on   the  ganglion  cells  of  Auerbach’s  plexus  and  on  
smooth muscle  fibers . Increase   the incidence of post – operative nausea and 
vomiting. Combination  of  atropine  with  neostigmine  has  been  found  to  
decrease  gastric cardiac  sphincter  pressure .Lower  portion  of  the  
oesophagus  is  stimulated  by neostigmine  resulting  in increase  in  tone  and  
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peristalsis . 
 
Genito – urinary tract: 
 
Stimulation  of  urethral  peristalsis  and  contraction  of  the  detrusor  muscle  of  
the urinary   bladder .The  external  sphincter  and  trigone  are  relaxed . 
 
Respiratory tract: 
 
Cholinergic  stimulation  of  bronchi  produces  bronchoconstriction  and  have 
potential  to  increase  airway  resistance . 
 
Glands: 
 
Augments  production  of  secretions  of  glands  innervated  by  postganglionic 
cholinergic  fibers  [  bronchial ,  lacrimal ,  sweat ,  salivary ,  gastric ,  intestinal , 
and  pancreatic  acinar  glands]. 
 
Eyes: 
 
Causes  constriction  of  iris – miosis  and  cilliary  muscle – inability  to  focus  for 
near  vision . Intraocular  pressure  declines  because  the  outflow  of  aqeous  
humor is  facilitated . 
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CLINICAL   USES: 
 
1. Antagonist-assisted reversal of neuromuscular blockade: 
          
Reflects  increased  availability  of  acetylcholine  at  the  NMJ  due  to  inhibition  
of  acetylcholinestrase .  Improves the chance of two acetylcholine molecules to 
the alpha subunit of the nicotinic cholinergic receptors. They  are  typically 
administered  during  the  time  when  spontaneous  recovery  from  
neuromuscular blockade  is  occurring  such  that   the  effect  of  pharmacologic  
antagonist  adds  to the  rate  of  spontaneous  recovery  from  the  
neuromuscular  blocking  drug .  
 
Neostigmine  appears  preferable  to  either  edrophonium  or  pyridostigmine  
when > 90 %  twitch  depression  is  to  antagonizedDose  of  neostigmine  
required  for  recovery  of  first  twitch  height  [ injected  when   twitch  height  is  
10 %  of  control ]  atracurium  induced  neuromuscular blockade . 
ED 50         -         10 micro gm / kg 
ED 80          -         22 micro gm / kg 
 
 
Recommended  doses  of  neostigmine  according  to  response  to  train – of - 
four stimulation . 
None  - none 
<2  - 0.07 mg / kg 
3- 4 -  0.04 mg / kg 
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The  dose  of  atropine  to  be  added  is  one –half  that  of  neostigmine . The  
dose  of  glycopyrollate  is  one – fourth  of  that  of  neostigmine . 
 
Events that influence reversal of neuromuscular blockade: 
1. Intensity  of  neuromuscular  blockade  at  the  time  of  pharmacologic  
reversal. 
2. Nondepolarising neuromuscular – blocking drug being reversed. 
3. Certain antibiotics. 
4. Hypothermia. 
5. Respiratory acidosis associated with a PaCO2 of   > 50 mmhg. 
6. Hypokalemia. 
7. Metabolic acidosis. 
 
Treatment of   Myasthenia gravis: 
   
Increases  the  response  of  skeletal  muscles  to  repetitive  impulses 
presumably  by  increasing  the  availability  of  endogenous  acetylcholine .  Oral 
dose of neostigmine is 30 times than the I.V.  Dose. The interval between the oral 
doses is usually 2 – 4 hrs. 
 
Post - operative analgesia: 
Intrathecal   injection  of  10 – 30  µg  produce  analgesia  without  ventilatory 
Depression , although  nausea  is  common . 
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ATRACURIUM 
 
 
Atracurium  is  a  bisquaternary   benzylisoquinolinium  nondepolarising 
neuromuscular  blocking  drug  [ mixture  of  ten  geometric  isomers ]  
 
ED 95  - 0.2mg / kg 
Onset   of   action. 
3 to 5 minutes. 
Duration of action. 
                       20 to 35 minutes. 
 
Site of action  
 
 Acts on both presynaptic and postsynaptic cholinergic receptors. Atracurium may  
also  produce  neuromuscular  blockade  by  directly  interfering  with passage  of  
ions  through  channels  of  nicotinic  cholinergic  receptors. 
 
 
 
Protein binding 
 
82  %  of  atracurium  is  bound  to  plasma  proteins , presumably  albumin  
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pH 
 
Adjusting  the  pH  of  commercial  solution  to  3.25  to  3.65  minimizes 
spontaneousin  vitro  degradation . Atracurium  probably  should  not  be  mixed 
with  alkaline drugs  or exposed  to  solutions  with  more  alkaline  Ph , as  are 
present  in  delivery  tubing  used  for  infusion  of  I.V .  Fluids.  
 
Solubility 
 
The iodide salt besylate provides water solubility. 
 
Temperature of storage. 
 
Atracurium   should be stored at 4 to 8 degree Celsius. Potency  of atracurium  
Stored  at  room  temperature  decreases  approximately  5 %  every 30 days . 
 
 
Clearance. 
 
Hoffmann   elimination;   spontaneous  non – enzymatic  degradation  at  normal 
body  temperature  and  pH  by  a  base  catalyzed  reaction A  second  and  
simultaneously  occurring  route  of  metabolism  is  hydrolysis  by  non – specific  
plasma  esterases . These  two  routes  of  metabolism  are  independent  of  
hepatic  and  renal function  as  well  as  plasma  cholinesterase  activity .Overall  
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ester  hydrolysis  accounts  for  estimated  2 / 3 rd  of   atracurium degradation, 
whereas  Hoffmann  elimination  provides  a  safety  net  especially  in  patients  
with  impaired  hepatic  and  renal  function . 
 
 
Laudanosine  is  the  major  metabolite  of  both  the  pathways  of  metabolism  
of atracurium  with Hoffmann elimination  resulting  in  2  molecules  and  ester 
hydrolysis  resulting  in  1  molecule of  laudanosine  for  every  molecule  of 
atracurium  that  is  metabolized .Electrophilic  acrylates  are  also  formed  by  
Hoffmann  elimination . 
 
 
Cumulative effects:  
 
Absence  of  significant  cumulative  drug  effect  is  due  to  rapid  clearance  of 
Atracurium  from  plasma  that  is  independent  of  renal  or  hepatic  function . 
Lack  of  a  significant  drug  cumulative  effect  minimizes  the  likelihood  of 
Persistent  neuromuscular  blockade  when  prolonged  surgical  procedures 
require  repeated  doses  or  a  sustained  continuous  infusion of  atracurium. 
    
Cardio - vascular    effects: 
              
 The rapid I.V.  administration  of  3 times ED  95  of  atracurium   increases  heart  
rate  by   8.3 %  and  decrease  mean  arterial  pressure  by  21.5 % . These 
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circulatory   changes  are  transient , occurring  60  to  90  seconds  after  
administration  of  atracurium and  disappearing  within  5  minutes .  Facial  and 
truncal  flushing  in  some  patients  such  as  release  of  histamine . If  the  same 
dose  of  atracurium  administered  over  30  to  75  seconds  or  rapidly  but  in 
patients  pretreated  with  H1  and  H2  receptor  antagonist  does  not  evoke 
circulatory  changes  despite  similar  increase  in  plasma  concentration  of 
histamine  as  present  in  those  receiving  the  same  dose  rapidly  without 
pretreatment  it  is  estimated  that  the  plasma  histamine  concentration  must  
double . 
  
Histamine  realease  evoked  by  atracurium  does  not  occur  repeatedly  
because tissue  istamine  stores  are  not  replenished  for  several  days . 
Therefore  a decrease  in  systemic  blood  pressure  due  to  drug  induced  
histamine  release is  less  likely  to  occur  to  the  same  magnidude  on  repeat  
dosing .CVS  effects previously  attributed  to  histamine  release  may  reflect  
prostacycline  releaseand  its  vasodilating  effects  on  peripheral  vasculature  
mediated  by  H1  and H2  receptors . 
      
 Pediatric patients: 
 
Effective  doses  of  atracurium  are  similar  in  adults  and  children  [2  to  16  –
Years  old ]  when  differences  in  extra  cellular  fluid  volume  or  minimized 
Calculating  the  dose  mg / sq.m  rather  than  a  mg / kg  basis Infants  1  to  6  
months  old  require  approximately  ½  the  dose  of  atracurium  given  to  older  
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children  to  achieve  the  same  degree  of  neuromuscular  blockade . These 
data  imply  that  infants  are  more  sensitive  than  children  or  adults . Recovery  
from  atracurium  – induced  neuromuscular  blockade , however ,  is  more rapid  
in  infants  [ 23 min ]  than  children  and  adolescents  [ 29 min ] . 
 
Elderly   patients: 
 
The  rate  of  recovery  and  the  duration  of  neuromuscular  blockade  is  similar  
in young  and  the  elderly . This  lack  of  influence  of  aging  on  dosing  of  
atracurium most  likely  reflects  the  independence  of  clearance  mechanism  
from  age - related effects  on  renal  and  hepatic  function . Changes  in  volume  
of  distribution  of atracurium  that  occur  with  aging  will  not  influence  the  
clearance  of   atracurium from  the  plasma . Failure  of  aging  to  alter  
responsiveness  of  the  the  NMJ  is documented  by  similar  plasma  
concentrations   of  atracurium  necessary  to  depress single  twitch  response  
50 %  in elderly and  young  adults . 
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5 NEUROMUSCULAR     MONITORING 
 
 
Neuromuscular  function  is  monitored by  evaluating  the  muscular  response  to 
Supramaximal  stimulation  of  a  peripheral  motor  nerve  . 
             
 Types of stimulation; 
        
   1.  Electrical 
   2.  magnetic 
  
Principles   of peripheral nerve stimulation 
 
The  reaction  of  single  muscle  fibre  to  a  stimulus  follows  an  all  or  none 
pattern. The  response  of  the  whole  muscle  depends  on  the  no . of  muscle  
fibres activated After  administration  of  neuromuscular  blocking  drugs  
response  of  the  muscle decreases   in  parallel  with  the  no  of  fibres  blocked 
.The  electrical  stimulus  applied  is  usually  at least  20 % - 25 %  above  that 
necessary  for  a  maximal  response  
Patterns   of   nerve   stimulation: 
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1. Single twitch stimulation:  
                             
Single supramaximal   stimuli is applied. Frequency of stimulation is from 1.0 HZ 
– 0.1 HZ. 1HZ stimulation shortens the time necessary to determine 
supramaximal stimulatio 
2. Train of four stimulation: 
                                
Introduced by Ali & associates in 1970s. Four  supramaximal  stimulation  are 
given  every  0.5  seconds  at  a  frequency  of  2HZ  When  used   continuously  
stimulation  is  repeated  every  10 th  or  20 th  second .Dividing  the  amplitude  
of  fourth  response  by  the  first  response  gives  the train of four ratio . Degree  
of  neuromuscular  block  can  be  read  from  T-O-F  response . Fade  in the T-O-
F after  succinylcholine  signifies   development  of  phase Π  block Less painful , 
unlike  tetanic  stimulation , does  not  affect  the  degree  neuromuscular block. 
 
3. Double-burst stimulation: 
 
Two short burst of 50 HZ tetanic stimulation separated by 750 msecs. Duration of  
each  square wave  impulse is  0.2 msec  Most  commonly used  is DBS  with  3  
impulse  in  each  of  two  tetanic  stimuli. In   non-paralysed  muscle two short 
muscle contractions of  equal  strengths  will be elicited .In partly paralysed 
muscle  the 2nd  response will be weaker .T O F       ratio closely  correlate  with 
D B S ratio DBS  was  developed  with  specific  aim of  allowing   manual  ( 
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tactile ) detection  of  small  amount  of  residual  blockade  during  recovery  and  
immediately  after  administration  of  anticholinesterase. Absence of fade in 
manual evaluation of   response to DBS does not exclude residual neuromuscular 
block. 
 
4.  Tetanic stimulation                                                                                                                 
                 
Tetanic stimulation consists of very rapid delivery of electrical stimuli. Most 
commonly used pattern in clinical practice is 50 HZ stimulation given for 5 sec. 
During  normal neuromuscular  transmission  and  a  pure depolarizing  block 
muscle  response  to  tetanic stimulation  is  sustained  but  during  a  non-
depolarizing  block  and  a  phase - 2  block , the  response  will  not  be    
sustained. Fade in response to tetanic stimulation   is normal considered a 
presynaptic event. Fade depends  primarily  on  the  degree  of  neuromuscular  
blockade and  also  depends  on  the  frequency ,  the  length of  stimulation  and  
on  how often  tetanic  stimuli  are  applied during  the partial  non- depolarizing 
blockade , the  tetanic  stimulation  is followed  by  a  post- tetanic  increase  in  
twitch  tension  ( post-tetanic  facilitation  of  transmission ) . The  degree  and  
duration  of  PTF  depends  on the degree of  neuromuscular  block with  PTF 
disappearing  within  60  seconds of  tetanic  stimulation very  painful, not  
acceptable  in  unanaesthetised  patient .In the late phase of neuromuscular  
recovery , tetanic  stimuli may  produce a  lasting  antagonism of neuromuscular. 
Tetanic stimulation has very little place in clinical anaesthesia. 
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5. Post – tetanic count stimulation: 
 
It  is  used  to quantify  intense  neuromuscular  blockade  (  i.e. TOF= 0 )  of  
peripheral  muscles  by  applying  tetanic  stimulation  (50HZ  for  5 secs)  and    
observing  the  post – tetanic  response  to  single  twitch  stimulation  given  at  1 
HZ   starting  3  seconds  after  the  end  of  tetanic  stimulation. The  time  until  
return  of  the  first  response  to  TOF  stimulation  is  related  to the  no  of  post 
– tetanic  twitch  responses  present  at  a given  time . The  main application  of  
PTC  is  evaluation  of  degree  of  neuromuscular  blockade  when there is no 
reaction to single  twitch  or  TOF  stimulation .PTC is also used whenever 
sudden movement should be eliminated and  to ensure  elimination  of  any  
bucking  or  coughing  in  response  to  tracheo-bronchial  stimulation  such  that  
the  neuromuscular  block should  be so intense that  no  response  to  post-
tetanic twitch stimulation can be elicited ( PTC = 0) .  The response to PTC 
stimulation depends primarily on the degree of neuromuscular blockade.  It  also 
depends  on  the  frequency  and  duration  of tetanic  stimulation and  the  first  
post – tetanic  stimulus ,  the  frequency of  the single  – twitch  stimulation , and  
the length of  single twitch stimulation before tetanic stimulation . 
 
Because of  possible  antagonism  of  neuromuscular  blockade tetanic 
stimulation  should not  be  given  more  often  than  every  6  minutes . 
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The    Nerve   Stimulator: 
         
The wave form should be monophasic and rectangular. 
The length of the pulse should not exceed 0.2 – 0.3 msec. 
Stimulation should be at constant current. 
Battery operated. 
Battery check is desirable. 
Should be able to generate 60-70 ma and not >80 ma 
Built –in warming system & current level display is Desirable. 
Polarity of electrodes should be indicated. 
 
Modes desirable  
 
TOF –single and repeatitive mode. 
Single twitch – 0.1 and 1.0 HZ  
Tetanic stimulation -50 HZ. 
Built in time constant system to facilitate PTC. 
Atleast one DBS – preferably DBS 3,3 . 
                                 
Stimulating   electrodes: 
   
Made of disposable pregelled silver or silver chloride surface electrodes of 
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conducting area 7-8 mm in diameter. When the needle electrodes are used.They 
should be placed subcutaneously but never in a nerve. 
 
Site of nerve stimulation: 
 
The Ulnar nerve is the most popular site .Electrode should be applied on the volar 
aspect of the wrist .Distal electrode is applied 1 cm proximal to the point at which 
the proximal flexion crease of wrist crosses radial side of the tendon to the flexor 
carpi ulnaris muscle .The proximal electrode should be placed 2-5 cm proximal to 
the distal electrode .The stimulation elicits finger flexion and thumb adduction. 
The placement of negative electrode distally elicits greatest neuromuscular 
response . 
Sensitivity of muscles to neuromuscular blocking drugs: 
 
Diaphragm is the most resistant of all the muscles to depolarizing and non- 
depolarizing drugs. It requires 1.4 to 2.0 times the drug than adductor pollicis. The 
onset of action time is shorter for diaphragm and recovery is shorter than 
peripheral muscles .Muscles of the larynx,and corrugator supercilli are less 
resistant than the diaphragm . Most sensitive are the abdominal muscles, 
orbicularis occuli, peripheral muscles of the limbs, geniohyoid ,massetter, upper 
limb muscles. 
 
Possible causes: a) Ach receptor density. b) Ach release c) CholinestraseActivity. 
d) Muscle fibre composition e) Innervation ratio (no of NMJ) f) Blood flow. g) 
Muscle temperature. 
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Other evoked muscle action potentials: 
 
Mechano –myography. 
Electro-myography. 
Accelero-myography 
Phono-myography. 
Peizo-electric myography. 
 
 
 
Use of   nerve stimulator without recording equipment: 
 
Tactile and visual evoked response is still the most common form of clinical 
neuromuscular monitoring. When possible ,the response to nerve stimulation 
should be evaluated by feel and not by eye and the thumb response rather than 
that of the fifth       finger should be evaluated .Both central and peripheral cooling 
should be avoided otherwise it may reduce the twitch tension and the TOF ratio , 
may affect nerve conduction , decrease the rate of release of  Ach ,and muscle 
contractility ,increase skin impedance ,and reduce the blood flow to the muscles.   
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During induction of anaesthesia: 
 
Should be attached to the patient before induction of anaesthesia but should not 
be turned on until after the patient becomes unconscious. Single twitch stimulus 
at 1HZ used to seek supramaximal stimulation. Change the mode to TOF. 
Neuromuscular blocking agent is injected. Trachea is intubated when response to 
TOF is zero. 
 
During   intra-operative period: 
 
The muscle response to TOF nerve stimulation reappears within 4-8 min the time 
until return of response to TOF stimulation may be evaluated by using the post-
tetanic count. 
Twitch depression of 90% will be sufficient .one or two the response to TOF 
stimulation can be felt. The patient may breath, hiccup, even cough at the depth 
of block. To ensure paralysis of diaphragm the blockade should be so intense that 
PTC-stimulation is zero at the thumb. 
 
 During reversal of neuromuscular blockade: 
 
Antagonism of non-depolarising block should not be initiated before atleast two 
response to TOF stimulation can be felt or before obvious clinical signs of 
returning neuromuscular function are present. To achieve rapid reversal (within 
 30 
 
 
 
 
 
10 min ) to a TOF ratio of 0.7 in more than 90% of  patients , three and preferably 
four responses should be present at the time of neostigmine  injection. Critical 
episodes of post-operative residual block should be an infrequent occurrence. For 
tactile evaluation greater sensitivity is achieved with DBS 3, 3. Even absence of 
manual fade in the DBS response does not exclude clinically significant blockade. 
Therefore, manual evaluation of response to nerve stimulation should always be 
considered in relation to reliable clinical signs and symptoms of residual 
neuromuscular blockade 
 
Clinical Test Of Post-operative Neuromuscular Recovery: 
 
Unreliable: 
 
Sustained eye opening. 
Protrusion of tongue. 
Arm lift to opposite shoulder. 
Normal tidal volume. 
Normal or near normal vital capacity. 
Maximum inspiratory pressure <40-50 cm H2O 
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Reliable: 
 
Sustained head-lift for 5 seconds 
Sustained leg-lift for 5 seconds  
Sustained hand-grip for 5 seconds. 
Sustained tongue depressor test. 
Maximum inspiratory pressure of > or = to 40-50 cm H2O. 
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 6 REVIEW OF LITERATURE  
 
 
Atracurium  besylate  is  an  non-depolarising  neuromuscular  blocking  drug  of 
intermediate  duration  of  action . It  has  unique  metabolism  of   non-specific  
esterase  hydrolysis  and  Hoffmann’s  elimination . Spontaneous  recovery  of 
residual  blockade  has  been  recorded   but  was  slow, needs  anticholinestrase 
neostigmine  to  facilitate  recovery   of   residual  blockade . 
 
Literature  was  reviewed  to  compare  the  recovery  of  residual  neuromuscular 
blockade  when  reversed  with  three  doses  in  descending  order ( 50 ,25 ,12.5 
µgms / kg )  of  neostigmine . 
 
1. Gencarelli  PJ  et  al39, ( 1982 )  studied  the  antagonism  of  ORG NC 45 
pancuronium  and  atracurium neuromuscular  blockade  by  neostigmine 
and  found  that  ED 80  for  pancuronium, vecuronium, and atracurium 
were 45, 24,and 22 µgms  respectively . 
 
 
2.    Cronnelly  R  et  al38, ( 1982 ) studied  edrophonium  : duration  of  action 
and atropine  requirement  in  humans  during  halothane  anaesthesia , and 
found that  ED 80 for  pancuronium , vecuronium , and atracurium  were 680 
, 460 , and 440 µgms / kg respectively . 
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3. Jones  JE  et  al7, ( 1988 )  studied  using  neostigmine  1.25 mg or 0.625 mg    
to  antagonize  neuromuscular  blockade  produced  by  either  atracurium 0.5 
mg   / kg  or  vecuronium  0.1 mg / kg in  four  group  of patients ( n = 45 ) 
when  the   first  EMG  response  of  the  train of four (A’0 had  recovered  to  
10 %  of   control  (A) . The  time  for  A / A’  and  train  of  four  ratio ( D’ /A’ )  
to  reach   70 %  was  recorded . It  was  found  that  , after  both  atracurium 
and  vecuronium  ,   neostigmine  1.25 mg  considerably  accelerated  the  
recovery  and  when  compared   with  previous  results  , differed  little  from  
neostigmine  5.0 mg or 2.5 mg .  
 
Neostigmine 0.625 mg also significantly accelerated recovery of after 
atracurium and was comparable to neostigmine 1.25 mg. However, with 
neostigmine 0.625 mg  after  vecuronium  , recovery  of  D’ / A’ ( but not A’ / A 
)  was  little  faster than  spontaneous  . Neostigmine  1.25 mg  appears  to  be  
almost  as  effective  as neostigmine 5 mg or 2.5 mg  in  antagonizing  
considerable  block ( 90 %  of    depression  of  twitch  height  )  produced  by  
either  atracurium  or  vecuronium , but  neostigmine  0.625 mg is  not  
sufficient , especially  after  vecuronium . 
 
   
4.  Erkola  O  et  al1 , ( 1989 )  studied  the  spontaneous  recovery  of  
atracurium  and   vecuronium  , monitored  electromyographically  during  0.5 
% isoflurane anaesthesia in  60 patients  undergoing  plastic  surgery . The  
recovery  time  from  T 1  75 %  to TOF  ratio  75 % , indicating  the  recovery  
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rate  of  residual  neuromuscular  blockade,with  atracurium  was  about  15 
min after  both  the  initial  and the  second  recoveries  With  vecuronium  , 
the  respective  recovery  times  were  significantly ( P less than)  longer        ( 
25.6 min and 38.5 min , respectively ) . It  is concluded  that  with vecuronium  
there  is  slower  spontaneous  recovery  of  residual neuromuscular blockade  
than  with  atracurium . 
 
5. Kirkegaard – Nielsen et  al2,   ( 1995 )  studied  to  determine  the  time  to  
peak  effect  of  neostigmine  ( time  to  peak antagonism ) during  vecuronium 
or atracurium induced  neuromuscular  block  and  to  determine  the  effect  
on  time  to  peak effect  of  neostigmine  during  atracurium  induced  
neuromuscular  block , when  the    dose  of  neostigmine  is  increased  from  
35 µ gm / kg  to  70 µgm / kg  and  concluded  that  the time  to  peak  effect   
of  neostigmine  35 µgm / kg is about  6 to  10 min when   antagonizing  a  
constant  degree  of  atracurium or  vecuronium  induced   neuromuscular  
block  at  a twitch  height  at  a  point  between  4% to  11% . Even    though  
the  time  to  peak  effect  was  longer  with  atracurium  than  with  
vecuronium clinically  significant  differences  between  the  antagonizing  
effect  of  atracurium   versus  vecuronium  block  was  not  demonstrated  . 
The  time  to  peak  effect   during  atracurium  induced  block  decreased  
when  the  dose  of  neostigmine  was  increased  from  35  to  70  µ gm / kg . 
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6.  Harper  NJ  et  al3,  ( 1994 )  studied  in  57  patients  undergoing  
gynecological    surgeries  to  establish  a  dose  response  relationship  when  
neostigmine  was   given  to  antagonize  atracurium  induced  block . 3 
groups  received neostigmine   20 ,40 ,80 µ gm / kg  at  5- 10 %  recovery  of  
compound  muscle  action potential   at the adductor  pollicis ( profound  block 
)  in which  antagonism  was  prolonged  by  reducing  the dose of 
neostigmine from  40 µgm to 20 µgm / kg , but not    shortened  by    
increasing  the  dose  to  80 µgm / kg . Another 3 groups  received one of 
these doses  at 40 – 50 % neuromuscular recovery ( light  block )  at this block 
there was  no  significant difference  between the 3groups in the time taken to  
reach  a  TOF ratio of 0.7 . It was suggested  that  smaller  doses of  
neostigmine than are given commonly  produce adequate  antagonism  of  
atracurium  induced  neuromuscular  block . 
 
7.  Neilsen  HK  et  al4,  ( 1994 )  studied  in  52 healthy  women  anaesthetized 
with thiopentone , fentanyl , droperidol , and nitrous oxide  in  whom  
spontaneous and  neostigmine  facilitated  recovery  of  atracurium induced 
neuromuscular block  monitored with  PTC of  TOF  stimulation  of  the  ulnar  
nerve  and     mechanomyography .  The  results  suggest  that  pre-reversal  
time  is the strongest  predictor  of  reversal  time  when  neostigmine  is  
administered  during  intense  atracurium  blockade  . To  achieve  the  optimal  
time  saving  effect  , neostigmine  must  be  given  18 min  ( the  time  saved  
by  giving   neostigmine )  plus  7  to  11 min  ( needed  for  neostigmine  to  
reach  its peak  effect ) giving  a total  of  25 to  29 min before  TOF ratio  0.7 . 
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As  TH 1 is  between  1% and 10% 25 to 29 min  before  TOF  ratio  0.70  is  
reached during  spontaneous  recovery  , the  optimal  level  of  
neuromuscular  blockade for  neostigmine  administration  in atracurium  
blockade  is  when  TH1 is between  1% and  10% . And  concluded  that  the  
reversal  time  can  be      predicted  as  27.3 min- ( 0.89 x  prereversal  time  ) 
and  the  optimal  time of  neostigmine  administration  in  atracurium  
blockade  appears  to  be  when  TH1 is  1% - 10% . 
 
 
8. Fox  MA   et  al5,  (  1987 )  studied  antagonism  of atracurium  induced      
neuromuscular  blockade  with  neostigmine  ( one  or  two  doses  of  2.5 mg ) 
was compared , using electromyography , with spontaneous recovery  . 
Spontaneous  recovery  to the TOF ratio of 70%  was  slow , in the order  of  1 
hr after  a  initial  dose of  0.5 mg / kg and  45 min after  incremental  dose  of  
0.2 mg / kg .It is concluded that antagonism of  atracurium  with  one  dose of 
neostigmine  is  usually desirable , that  two  doses  are unnecessary  , and 
that the spontaneous recovery is slower  than is  generally  realized . 
 
9. Goldhill  DR  et  al6,  (  1991 )  studied  in  36 patients in  whom  anaesthesia  
was maintained  with  nitrous oxide and 0.5% isoflurane  an  atracurium – 
induced neuromuscular  block  was either  allowed  to  recover  spontaneously  
or antagonized       with  one of  4  doses  of  neostigmine (  15 ,35 ,55 , 75 µ 
gm / kg ) .There  appears no  benefit  in  giving  a  larger  dose than 35 µgm / 
kg of  neostigmine  as  a single  bolus.  
 37 
 
 
 
 
 
 
10. Stirt   JA   et  al11,  ( 1983 )  studied  effects of  halothane  and  of  prior   
     administration of suxamethonium  on  atracurium  neuromuscular  blockade .   
Halothane potentiated the intensity of block produced by atracurium 0.1 or   
0.15 mg / kg. Duration of block  was prolonged  ( 27 % ) by halothane with  a 
small dose  of  atracurium ( 0.15 mg /kg ) and  was  also prolonged  ( 29 % )  
with larger  doses  of  atracurium ( 0.4 mg  /kg ) . Prior  suxamethonium  1 mg 
/ kg increased  intensity of  block after atracurium  0.15 mg / kg from 52 % ( 
control ) to 84 % , but caused  minimal  change in duration  of  atracurium  
blockade . 
 
11. Chapple  DJ  et  al15,  ( 1983 ) studied  the  effects  of  various  drugs  used  
during       anaesthesia  on the  neuromuscular  blocking effect of atracurium  . 
Clinically effective  doses  of diazepam, morphine, pentazocine, pethidine, 
ketamine ,althesin,  methohexitone, septrin, lignocaine , propranolol, calcium 
chloride or azathioprine did  not  significantly  alter the action of  atracurium . 
Recovery of from atracurium was not prolonged during an infusion of 
hexamethonium or sodium nitroprusside , indicating  that , despite  the severe 
hypotension  , the inactivation of atracurium was unimpaired . The action of 
atracurium was enhanced by tubocurarine, halothane, gentamycin , neomycin 
, and polymixin and was antagonized by adrenaline and transiently  by  
suxamethonium . However, pretreatment with suxamethonium did not affect 
the subsequent block by atracurium. 
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12. Parker  C J   et  al22,  ( 1993 ) studied  in  38 patients  the  plasma  
concentration profile  of  atracurium  and its  effect on the  electromyographic  
first response of the TOF . One of  3  techniques  was used to supplement  
anaesthesia  with  66 % nitrous  oxide  in  oxygen  , 0.9 % isoflurane ,0.5 % 
halothane ,or midazolam   3- 10 mg . A  four  parameter  threshold  
pharmacodynamic  model was fitted  to  the data  in each  patients .Compared  
with a group of  patients  anesthetized with  an i.v. technique  , the steady 
state plasma concentration producing  50% block was reduced by halothane 
and to a greater extent by isoflurane .The rate constant for exit from the effect  
compartment  correlated  negatively with age and was greater  in female 
patients , but unaffected by anaesthetic technique .The values of  gamma , the 
slope of the concentration response curve , and of the threshold were  not  
affected  significantly  by  age, sex ,or anaesthetic technique . 
 
13. Astley  BA  et  al25,   ( 1986 ) studied  the recovery of respiration following     
neuromuscular  blockade  with  atracurium 0.3 mg / kg in one  group  and 0.2 
mg / kg of alcuronium in another  group , judged  by  serial measurement of 
tidal volume , blood  gas values , and peripheral  neuromuscular function 
judged by the response  of the  adductor pollicis muscle were studied . 
adequate recovery  of  respiratory  muscle function was present in atracurium 
group within 15 min of the onset of  spontaneous respiration , whereas  in 
alcuronium group  took  30 min . At this time there was marked peripheral 
neuromuscular blockade with peak tetanic height values less than 25% of 
control in both groups. It was concluded that recovery of the respiratory  
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muscles from neuromuscular block by atracurium and alcuronium occurred 
more rapidly than the recovery of  small muscles of the hand , but that 
adequate  tidal volume , in the absence of other clinical  signs , should not be 
regarded as a  reliable  indication  of  complete return of  neuromuscular 
function. 
 
14. Jones  RM  et  al26,  ( 1984 )  studied  the evoked  reversal  characteristics of  
atracurium in 21 patients using  edrophonium or neostigmine and a TOF 
pattern of stimulation.  Reversal with edrophonium was more rapid than with 
neostigmine. A  T4 ratio of      0.5 was confirmed to be compatible with the 
reliable and safe reversal of atracurium      induced neuromuscular blockade. 
 
15. Kirkegaard – Neilsen  et  al36,  ( 1995 )  studied  in  44  women  scheduled  
for  gynecological surgeries  to evaluate the use of tactile  responses  of  
adductor  pollicis  to  DBS  and  TOF for  monitoring  moderate and  profound  
levels  of  neuromuscular  blockade . The  tactile responses  are  compared  
with  mechanomyographical  measurements  in  the  contralateral  arm  during  
recovery  from  neuromuscular  blockade . Time  from  injection  of  the  initial 
dose  of  atracurium  until  tactile  reappearance  of the  first  twitch  in  DBS  
was 24.6 min median . This  was  more  rapid  than  the  time  until 
reappearance  of   the  first  twitch in  TOF  32.8 min  ( P < 0.05 )  . It  is  
concluded  that  tactile  evaluation  of  responses  of   DBS   stimulation  can  
estimate  deeper  levels  of  blockade  than  evaluation  of  responses  to TOF. 
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7 MATERIALS   AND   METHODS  
 
 
This  study  was  conducted  at  Government  Stanley  Hospital , Chennai  in  the  
patients  undergoing   adeno-tonsillectomy ,and  tonsillectomy. 
 
After  institutional  approval  and  informed  consent , 90  patients  were  enrolled  
in  the  study . 
 
INCLUSION   CRITERIA: 
 
All   ASA  physical  status(1 & 2)  patients  aged  between  5 – 15  years  
scheduled  for  tonsillectomies and  adeno  - tonsillectomies  under  general  
anaesthesia  . 
 
EXCLUSION   CRITERIA:  
 
1. Neuromuscular disease. 
2. Patients receiving any medication known to interact with neuromuscular   
blocking agents 
3. Known allergy to any medication.  
4. Anticipated   difficult   intubation. 
5. Morbidly obese  
6. ASA   physical   status   3, 4, & and 5. 
7. Age  below  5  years  and  more  than  15  years  . 
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PREOPERATIVE    EVALUATION: 
 
In  all  the   patients  age ,  body  weight , preoperative  blood  pressure , and  
pulse  rate  were recorded .History  regarding  previous  anaesthesia  and  
surgeries , any  significant  medical illness , medications and  allergy  were  
recorded . 
 
Complete physical examination and airway assessment was done. 
 
Following laboratory investigations were done. 
 
1. Haemoglobin %, packed cell volume. 
2. Urine – albumin, sugar. 
3. Bleeding time, and clotting time. 
4. Blood - sugar, urea, creatinine. 
5. Chest x-ray. 
6. Electrocardiogram 
 
PREMEDICATION: 
 
All  patients  received  injection  atropine  20  µgm / kg  intramuscularly  at least  
1hour  prior to  surgery . 
 42 
 
 
 
 
 
 
INDUCTION OF ANESTHESIA: 
 
On  arrival  in  the  operating  room  intravenous  access  was  secured  with  22G 
,20G, 18G cannula  in  a  vein  in  the  dorsum  of  hand . Isolyte – P infusion was 
started.                             
 
Following monitors are connected to the patient: 
 
1. Non invasive blood pressure  
2. Precordial  sthethoscope 
3. Electrocardiogram  
4. Pulse oximeter. 
5. Neuromuscular monitor. 
 
Basal recordings were noted. 
 
The  neuromuscular  monitor  was  connected  to  the  patients  forearm  in  which 
the ulnar  nerve  is  stimulated  and  contraction  of  the  adductor  pollicis  is  to  
be monitored   the  patients  were  systematically  randomized  into  three  groups  
of  thirty  each. Each   patient was given injection pentazocine 0.5 mg / kg 
intravenously. After  preoxygenation for  3 minutes , anaesthesia  was  induced  
with  injection thiopentone 5 mg / kg over  20 seconds, after  the  patient  
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becomes  unconscious  single  twitch  stimulation  was  used  in  1HZ  to  
determine  the  supramaximal  stimulation  current  strength  required. An  
intubating  dose  of  injection  atracurium 0.5 mg / kg given  intravenously  and  
mask  ventllation  with  oxygen  6 lpm  done  for  3-4 minutes  and  then  
endotracheal  intubation  done  .Anaesthesia   was  maintained   with  nitrous – 
oxide  ( 66 % ) and  oxygen  (  33 % ) and  halothane was  used  in  0.5 %  
concentration. Muscular relaxation maintained with top-up doses of atracurium 
0.15 mg / kg. 
 
AFTER    THE   SURGICAL    PROCEDURE: 
 
At  the  end  of  surgical  procedure  , the time when  spontaneous  respiration  
attempts  are  reappearing, the  number  of    responses  to  train  of  four  
stimulation at that time was recorded. The patients were systematically 
randomized into three   groups of thirty each. When  the  train  of  four  response  
recorded  was  3  or  4 , Reversal  of  neuromuscular  blockade  was  given  as  
follows,  
Group  A  - Neostigmine  50 µgm / kg  + Atropine 20 µgm / kg . 
Group  B  - Neostigmine  25 µgm / kg + Atropine  20 µgm / kg . 
Group  C  -Neostigmine  12.5 µgm / kg + Atropine 20 µgm / kg . 
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The following observations were recorded: 
 
1. AT   THE TIME OF NEOSTIGMINE ADMINISTRATION. 
 
The  heart  rate , blood  pressure , oxygen  saturation , time  duration  from  last  
dose  of  Atracurium  to  administration  of  reversal , and  number  of  responses  
to  TOF   stimulation at  the  time  of  administration  of  reversal  were  recorded .   
     
    
2. AFTER     ADMINISTRATION    OF    NEOSTIGMINE  
a)  Neuromuscular recovery:  
 
1.   Time required for responses to TOF stimulation without fade from   
administration of neostigmine. 
 
2.   Time   required  for  responses  to  DBS  stimulation without   fade  from  
administration  of  neostigmine  . 
 
3.   Time  required  for  clinical  signs  (sustained  head  &  leg  lift   & eye  
opening  & hand  grip) to  become  positive  from   administration  of  
neostigmine . 
 
b) Haemodynamic   changes: 
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Heart  rate , blood  pressure ,  monitored  every  5 minutes for   1hour   after  
neostigmine  administration   and   minimum  and  maximum  parameters  are  
recorded . 
 
c) Adverse side effects:          
 
Patients were monitored for nausea, vomiting, bradycardia,    and   hypotension    
were recorded. 
STATISTICAL     ANALYSIS: 
The  data  was  computed  and  all  values  expressed  as  mean  +/-  S.D.  The  
data  was  analyzed  using  student  independent  t  test  , anova  F  test  and  
Chi-square  test  as  appropriate  . 
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8 OBSERVATIONS  
 
 
The study was conducted on 90 patients randomly allotted into three groups as 
given below. 95% Confidence level assumed for statistical tests. 
 
 
 
DRUG DOSAGE AND SCHEDULE 
 
 
 
Group Dose of Neostigmine Sample size Abbreviation 
A 50 microgram/kg 30 N1 
B 25 microgram/kg 30 N2 
C 12.5 microgram/kg 30 N3 
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DEMOGRAPHIC PROFILE 
 
 
Age, Sex, Weight and Physical status are compared between three groups. 
 
 
 
AGE DISTRIBUTION 
 
 
Age Group A Group B Group C 
5 – 10 17 14 16 
11 – 15 13 16 14 
 
Mean Age +/- SD 9.73 +- 3.352 10.17 +- 3.239  10.0 +- 3.14  
   
P Value – 0.87 – Not Significant (Using ANOVA F Test) 
 
 
 
 
 
SEX DISTRIBUTION 
 
Sex Group A Group B Group C 
Male 14 16 16 
Female 16 14 14 
 
P Value – 0.84 – Not Significant (Using Chi-square Test) 
 
 
 
 
 
 
 
 48 
 
 
 
 
 
 
 
 
WEIGHT DISTRIBUTION 
 
 
Weight Group A Group B Group C 
1 – 10 0 1 0 
11 – 20 11 9 8 
21 – 30 11 10 13 
31 – 40 8 10 9 
 
 
Mean Weight +/- SD   26.33 +- 7.608  25.77 +- 7.592   26.77 +- 7.749 
 
 
P Value – 0.88 – Not Significant (Using ANOVA F Test) 
 
 
 
 
PHYSICAL STATUS DISTRIBUTION 
 
 
Physical status Group A Group B Group B 
PS – 1 22 20 21 
PS – 2 8 10 9 
 
 
P Value – 0.857 – Not Significant (Using Chi-square Test) 
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OBSERVATIONS    BEFORE    NEOSTIGMINE    ADMINISTRATION  
 
TIME DURATION FROM LAST DOSE OF ATRACURIUM (MIN) 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 21.6 4.166 
Group B 30 20.37 3.891 
Group C 30 20.6 3.856 
Total 90 20.86 3.965 
0.82 0.45 
 
P Value – 0.82 – Not Significant (Using ANOVA F Test) 
 
NO OF TOF RESPONSE AT REVERSAL 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 3.53 0.507 
Group B 30 3.6 0.498 
Group C 30 3.6 0.498 
Total 90 3.58 0.497 
0.18 0.84 
 
P Value – 0.84 – Not Significant (Using ANOVA F Test) 
 
HEART RATE (BPM) BEFORE NEOSTIGMINE ADMINISTRATION 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 109.77 10.9 
Group B 30 104.80 9.496 
Group C 30 108.33 13.231 
Total 90 107.63 11.381 
1.5 0.22 
P Value – 0.22 – Not Significant (Using ANOVA F Test) 
 50 
 
 
 
 
 
 
SYSTOLIC BLOOD PRESSURE BEFORE NEOSTIGMINE 
ADMINISTRATION 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 107.33 12.299 
Group B 30 109.33 11.121 
Group C 30 108.33 11.472 
Total 90 108.33 11.539 
0.22 0.80 
 
P Value – 0.80 – Not Significant (Using ANOVA F Test) 
 
DIASTOLIC BLOOD PRESSURE BEFORE NEOSTIGMINE 
ADMINISTRATION 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 70.67 10.807 
Group B 30 73.67 6.687 
Group C 30 68.67 6.814 
Total 90 71.00 8.487 
2.74 0.07 
 
P Value – 0.07 – Not Significant (Using ANOVA F Test) 
 
OBSERVATIONS    AFTER   ADMINISTRATION   OF   
NEOSTIGMINE: 
 
TIME REQUIRED FOR TOF RESPONSE WITHOUT FADE (MIN) 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 4.27 1.76 
Group B 30 5.17 2.001 
Group C 30 5.73 2.363 
Total 90 5.06 2.122 
3.88 0.02 
 
P Value – 0.02 –Significant (Using ANOVA F Test) 
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P – Value shows significant difference. The time duration is very small and hence  
 
the difference in mean values can be neglected. 
 
TIME REQUIRED FOR DBS RESPONSE WITHOUT FADE (MIN) 
 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 4.83 1.821 
Group B 30 5.63 1.866 
Group C 30 6.03 2.236 
Total 90 6.37 2.106 
2.85 0.07 
 
P Value – 0.07 – Not Significant (Using ANOVA F Test) 
 
 
TIME REQUIRED FOR CLINICAL SIGNS TO BE POSITIVE (MIN) 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 5.967 1.7515 
Group B 30 6.2 1.9546 
Group C 30 6.93 2.4904 
Total 90   
1.74932 0.179 
 
P Value – 0.179 – Not Significant (Using ANOVA F Test) 
 
TIME REQUIRED FOR EXTUBATION FROM NEOSTIGMINE 
ADMINISTRATION (MIN) 
 
Group N Mean Std.Dev ANOVA F-
Test 
P – Value 
Group A 30 7.93 1.837 
Group B 30 8.27 2.196 
Group C 30 8.93 2.572 
Total 90 8.38 2.236 
1.58 0.21 
P Value – 0.21 – Not Significant (Using ANOVA F Test) 
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COMPARISON OF HAEMODYNAMIC PARAMETERS BEFORE 
AND AFTER NEOSTIGMINE ADMINISTRATION 
 
Systolic Blood Pressure 
 
Group SBP Mean N Std.Dev t-Test P – 
Value 
SBP(Basal) 107.33 30 12.299 Group – 
A SBP(Mean) 105.5 30 7.233 
0.727 0.472 
 
P Value – 0.472 –Not Significant (Using Paired sample t-Test) 
 
 
Group SBP Mean N Std.Dev t-Test P – 
Value 
SBP(Basal) 109.33 30 11.121 Group – 
B SBP(Mean) 109.33 30 6.91 
0 1.0 
 
P Value – 1.0–Not Significant (Using Paired sample t -Test) 
 
 
 
Group SBP Mean N Std.Dev t-Test P – 
Value 
SBP(Basal) 108.33 30 11.472 Group – 
C SBP(Mean) 111.66 30 8.937 
-2.65 0.012 
 
P Value – 0.012–   Significant (Using Paired sample t -Test) 
 
 
Diastolic Blood Pressure 
 
Group DBP Mean N Std.Dev t-Test P – 
Value 
DBP(Basal) 70.67 30 10.807 Group – 
A DBP(Mean) 69.66 30 6.149 
0.468 0.643 
 
P Value – 0.643– Not Significant (Using Paired sample t -Test) 
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Group DBP Mean N Std.Dev t-Test P – 
Value 
DBP(Basal) 73.67 30 6.687 Group – 
B DBP(Mean) 71.66 30 4.97 
1.88 0.069 
 
P Value – 0.069–Not Significant (Using Paired sample t -Test) 
 
 
Group DBP Mean N Std.Dev t-Test P – 
Value 
DBP(Basal) 68.67 30 6.814 Group – 
C DBP(Mean) 70.83 30 6.02 
-2.212 0.0349 
 
P Value – 0.0349–Significant (Using Paired sample t -Test) 
 
Heart Rate 
Group Heart Rate Mean N Std.Dev t-Test P – 
Value 
Heart 
Rate(Basal) 
109.77 30 10.9 
Group – 
A Heart 
Rate(Mean) 
90.63 30 14.98 
8.37 0.001 
 
P Value – 0.001–Significant (Using Paired sample t -Test) 
 
 
Group Heart Rate Mean N Std.Dev t-Test P – 
Value 
Heart Rate 
(Basal) 
104.8 30 9.496 
 Group – 
B Heart Rate 
(Mean) 
106.33 30 8.22 
 
-0.935 
 
0.35 
 
 
P Value – 0.35–Not Significant (Using Paired sample t -Test) 
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Group Heart 
Rate 
Mean N Std.Dev t-Test P – 
Value 
Heart 
Rate 
(Basal) 
108.33 30 13.231 
Group – 
C Heart 
Rate 
(Mean) 
115.01 30 11.92 
-6.657 0.001 
 
P Value – 0.001–Significant (Using Paired sample t -Test) 
 
 
 
OXYGEN SATURATION 
 
 
P- Value 0.001 - Significant (Using Paired sample t- test) 
 
 
 
P- value 0.86 -Not significant (Using paired sample t-test) 
 
                                         
Group Spo2 Mean N Std.Dev t-Test P – 
Value 
SPO2 
(Basal) 
98.86 30  
Group – 
A SPO2 
(Mean) 
98.35 30 0.374 
3.618 0.001 
Group Spo2 Mean N Std.Dev t-Test P – 
Value 
SPO2 
(Basal) 
98.46 30  
Group – 
B SPO2 
(Mean) 
98.45 30 0.15 
0.166 0.86 
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P value 1.0 -Not significant (Using paired sample t- test) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Spo2 Mean N Std.Dev t-Test P – 
Value 
SPO2 
(Basal) 
98.8 30  
Group – 
C SPO2 
(Mean) 
98. 30 0.3619 
0.0 1.0 
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9 RESULTS 
 
1.   Statistical analysis by    Anova – F test and Chi- square test showed there is   
no significant  differences   in  distribution    of   age , sex , weight , and  
physical    status between  the  three  study   groups . 
 
2.  Statistical analysis by Anova – F test showed that the      
 
a) The  time  required  for  the  TOF  response  to  recover  without  fade  
showed  a mean  as  group A ( 4.27 +/- 1.76 min ), group B ( 5.17 +/- 2.001 
), group C 5.73 +/- 2.122 )   Anova-F test -3.88, P  value  0.02   shows  a  
negligible  statistical  significance  in  speed  of  recovery  of  response to  
TOF  stimulation. 
    
b) The time  required  for  the  DBS  response  to  recover  without  fade  
showed  a 
mean  as  group A ( 4.83+/- 1.821 ), group B ( 5.63+/- 1.866 ), group C  ( 
6.03+/- 2.236 ) Anova-F test  2.85 , P value  0.07  shows  there  is  no  
statistical significance  among  three  groups  in  speed  of  recovery  of  
response  to  DBS  stimulation. 
     
c)   The  time  required  for  recovery  of   clinical  signs  of  adequate  muscle  
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power  showed  a  mean  for  group  A  ( 5.967+/-1.7515) , group  B ( 
6.2+/-1.9546 ) , group C ( 6.93+/-2.4904 ) Anova –F test  1.749 ,P- value  
0.179  shows  there  is no  statistical  significance  in  recovery  of  muscle  
power  after  neostigmine  among three  groups .  
 
c) The  time  required  for  extubation  after  administration  of  neostigmine  
showed a  mean  for  group A ( 7.93+/- 1.837 ) , group B ( 8.27+/- 2.196 ), 
group C  (8.93+/- 2.572)  Anova –F  test  1.53 , P value  0.21  shows  there  
is  no  statistical significance  among  the  three  groups  in  time  required  
for  extubation . 
 
3)  Effective  extubation  conditions  are  observed  in  all  patients  in  all  the  
three groups even though  the  dose  of  neostigmine  was  reduced  in  
groups  B & C . 
 
4)  Statistical  analysis  by  paired  sample  t- test  showed  that  the  mean  heart  
rate , systolic blood  pressure , diastolic blood  pressure , are  higher  in  
Group – C  than  the  other  groups 
      
Group C (115.01+/-11.97, 111.6+/- 8.937, 70.83+/-6.02) 
Group B (106.33+/- 8.22, 109.33+/- 6.91, 71.66+/- 4.97) 
Group A (90.63+/-14.98, 105.5+/-7.233, 69.66 +/- 6.149). 
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10 DISCUSSION 
 
In patients undergoing general anaesthesia requiring muscle relaxation with non - 
depolarising neuromuscular blocking drugs at the end of the surgical procedure 
the residual neuromuscular blockade needs to be reversed with anticholinestrase 
drugs like neostigmine which facilitates recovery from NMJ blocking agents so 
that patient recovers adequate muscle power to protect the airway , maintain 
breathing without external assistance . 
 
Though spontaneous recovery from NMJ blocking drugs can occur through their 
metabolism and excretion .The process is very slow and time consuming and 
without documented evidence of TOF ratio of 0.9 and sufficient signs of clinical 
muscle power recovery, spontaneous recovery from NMJ blocking drugs could 
not be allowed without reversal agents. 
 
Atracurium an NMJ blocking agent of intermediate duration of action has a novel 
metabolism which does not depend on hepatic or renal function. It has a potential 
to recover spontaneously even in patients with hepatic / renal failure. 
 
According to “Stoelting – textbook of pharmacology & physiology40 “, atracurium 
residual blockade requires lower dose of neostigmine (ED – 80 – 22µg/Kg) 
 
In our study 3 doses of Neostigmine, in descending order from 50 µg/Kg, 25 
µg/Kg, and 12.5 µg/Kg were compared in their ability to reverse atracurium in 
these residual NM Blockade in patients undergoing short surgical procedure – 
 59 
 
 
 
 
 
Adenotonscillectomy and Tonscillectomics in the age groups of 5 years to 15 
years with each group of 30 Nos. 
 
The groups are compared based on the time duration of recovery of 4 responses 
to train of four stimulation of ulnar N, at wrist (Adductor policies), without fade 
recovery of 2 responses to double burst stimulation of Adductor policies without 
fade and time required for extubation of patient in each groups and recovery of 
reliable clinical signs of NM recovery. 
 
The Adductor policies responds to train of four and double burst stimulation are 
assessed visually and manually (tactile) and not by graphical record. 
 
The associated side effects and haemodynamic changes, respiratory rate and 
oxygen saturation are observed for 60min, after the administration of neostigmine 
in each group. 
 
EXTUBATING CONDITIONS 
 
Jones J.E. etal7 (1988) showed that NM blockade produced by atracurium 
0.5mg/Kg can be reversed with 1.25mg and 0.625mg neostigmine and both the 
groups had significant acceleration of recovery and differed little from neostigmine 
5mg or 2.5mg but when vecuronium was reversed with 1.25mg and 0.625mg of 
neostigmine, the 0.625mg of neostigmine is not sufficient after vecuronium. 
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Erkola O et al1 (1989) showed in 60 patients undergoing plastic surgery were 
given atracurium and vecuronium monitored electromyographically during 0.5% of 
Isofurane anaesthesia. The spontaneous recovery to POF ratio 75% was about 
15 min. compared to 25.6 to 38.5 min with vecuronium. 
 
Kirkegaard – Nielson et al2 (1995) showed time to peak effect during atracurium 
induced block, decreased when the dose of neostigmine was increases from 35 – 
70 µg/Kg and concluded that the time to peak effect of neostigmine 35µg/Kg is 
about 6 – 10min when antagonizing constant degree of atracurium induced NM 
Blockade at a twitch height at a point between 4% - 11% 
 
Nielsen HK et al4 ( 1994 ) showed the optimal level of NM Blockade for 
neostigmine administration when atracurium blockade is TH1 is between 1% and 
10% and optimal time to give neostigmine from the last dose of atracurium must 
be 18min and concluded that reversal time can be predicted as 27.3min (0.89 x 
Pre reversal time) 
 
FOX M A et al5 (1987) showed spontaneous recovery of TOF ratio to 70% is 1 hr 
after initial dose of 0.5mg/Kg and 45min after incremental dose of 0.25mg/Kg  
and that the spontaneous recovery is slower than generally recognized and it is 
concluded that antagonism of atracurium with 1 dose of neostigmine is usually 
desirable. 
 
GOLDHILL D R et al6 (1991) showed that in 36 patients maintained with nitrous 
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oxide and 0.5% of Isoflurane and atracurium induced NM Block reversed with  1 
of 4 doses of neostigmine (15, 35, 55, 75µg/Kg) concluded that no benefit in 
giving a larger dose than 35µg of neostigmine as a single bolus. 
 
ASTLEY B A et al25 (1986) showed the recovery of respiration following NM 
blockade with atracurium was within 15min of last dose of atracurium before 
adequate recovery of peripheral NM function judged by response of adductor 
policies muscle and showed that adequate tidal volume in the absence of other 
clinical signs and should not be regarded as reliable indication of complete return 
of NM function. 
 
In the present study neostigmine was administered after recovery of spontaneous 
breathing efforts and number of TOF response was (mean group A – 3.53, group 
B – 3.6,  group C – 3.6, P – value – 0.84) between 3 and 4 and among the 3 
groups, no. of TOF response at reversal is not significant. 
 
After administration of neostigmine time required for TOF response recovery 
without fade in min had a mean of 4.27 min in group – A, 5.17 in group – B, 5.73 
in group – C. This minor difference in speed of recovery was shown to be 
significant by statistical test. The P – value 0.02 even though clinically not 
significant. 
 
Time required for DBS response without fade (min) showed a mean of 4.83 in 
group – A, 5.63 in group – B, 6.03 in group – C. P – Value of 0.07. There is no 
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significant statistical difference among the 3 groups. 
 
When comparing time required for extubation from neostigmine 
administration(min) showed mean of 7.93 in group – A, 8.27 in group – B, 8.93 in 
group – C and there is no statistically significant difference. 
 
Clinically acceptable extubating conditions are obtained in all the 3 groups under 
study and all the patients had reliable signs of clinical muscle power recovery for 
extubation. The  mean  time  for  recovery  of  adequate  muscle  power  were  
group  A – 5.97 , group  B – 6.2 , group  C – 6.93 min , P- value  is  0.179   shows  
there  is  no  statistical  significance  among  the  three  groups . This shows 
atracurium induced neuromuscular blockade could be reversed with clinically 
insignificant difference in speed of recovery even with lower dose of neostigmine 
(25µg, 12.5µg). 
 
HAEMODYNAMIC   CHANGES  
 
The neostigmine is an anticholinestrase. In addition to nicotinic receptor effects, it 
also acts on the muscarinic receptors and can produce parasympathomimetic 
action on the heart and slows down the heart rate. To avoid the muscarinic 
effects of neostigmine an anticholinergic drug like atropine is given along with 
neostigmine.  
 
In our study the group A (50µgm/kg) had significant reduction in mean heart rate 
after administration of neostigmine (90.3+/-14.98) compared with the mean of 
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heart rate before neostigmine administration (109.76+/-10.9) P value 0.001. The 
group C had significantly higher heart rate (115.01+/-11.97 ) compared with mean 
of basal heart rate ( 108.33+/-13.231), this may be due to the unopposed action 
of atropine because of the lower dose of neostigmine in group C ( 12.5 µgm/kg ) . 
 
In the group A 2 patients had bradycardia (58, 59 respectively) treated with 
atropine 20µgm/kg. This may be because of neostigmine administration in higher 
dose (50µgm/kg) 
 
The group A and B had no significant difference in systolic and diastolic blood 
pressures when compared with systolic and diastolic blood pressure before 
neostigmine administration. 
 
The group C had statistically higher systolic blood pressure ( 111.6+/-8.937) than 
the basal value ( 108.33+/-11.472) and statistically significant increase in diastolic 
blood pressure ( 70.83+/-6.02 ) compared with basal values (68.66+/-6.814 ).But 
these changes in the diastolic blood pressure are clinically insignificant .  
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ADVERSE EFFECTS 
The adverse effects looked upon were nausa, vomiting, bradycardia, hypotension 
because of the muscarinic effect of neostigmine. 
 
 
In our study only two patients of group A had bradycardia and no patient in any of 
the three groups had nausea or vomiting or hypotension. The bradycardia was 
treated with atropine 20µgm/kg intravenously. 
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11 SUMMARY 
 
1.   The lower doses of neostigmine (25 µgm/kg, 12.5 µgm/kg) provided equally 
effective reversal of atracurium induced neuromuscular blockade as the higher 
dose (50µgm/kg) 
 
2.   The  mean  time  required  for  recovery  of  adequate  muscle  power  after  
neostigmine  in  all three  groups  were  approximately  equal  and  difference  
among  them  were  statistically insignificant  ( 5.97+/-1.7515, 6.2+/-1.95. 
6.93+/-2.49 ) .   
 
3.   The mean time required for extubation in all the three groups approximately 
equal (7.93+/-1.837, 8.27+/-2.196, 8.93+/-2.572 respectively) 
 
4.  The mean time for the recovery of the two responses to DBS without any fade 
in response was also approximately equal in all the three groups (4.83+/-
1.821, 5.63+/-1.866, 6.03+/-2.236) 
 
5.  The heart rate showed a significantly lower mean value in group A 
(neostigmine 50µgm/kg) 90.63+/-8.37 compared with basal value 109.76+/-
10.9.  
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6. The group A had 2 patients with significant bradycardia who received the 
higher dose (50µgm/kg) of neostigmine  
7.   No patient in any of the three groups had side effects like nausea, vomiting, or 
hypotension. 
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12 CONCLUSION 
1.   Satisfactory facilitation of recovery from residual neuromuscular blockade 
produced by atracurium (given in intubating dose 0.5mg/kg and incremental 
dose of 0.15 mg/kg) are achieved with reduced doses of neostigmine 
(25µgm/kg and 12.5 µgm/kg).  
 
 
2.   Lower doses of neostigmine avoid the significant decrease in heart rate. 
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PROFORMA 
 
A  STUDY  COMPARING  THREE  DIFFERENT  DOSES  OF  
NEOSTIGMINE  ( 50µgm/kg, 25µgm/kg,12.5µgm/kg )  AS  
REVERSAL  AGENT  FOR  FACILITATION  OF  RECOVERY  FROM  
RESIDUAL  NEUROMUSCULAR  BLOCKADE  WITH  
ATRACURIUM . 
 
Name  :                                                                            Group : 
Age  :                                                                               Sex  : 
Ip. No  : 
Weight : 
Unit  : 
 
PREOPERATIVE    ASSESSMENT:  
 
Airway   :                               Hb  : 
General condition  :                           Urine  :   Albumin. 
Pulse rate    :                                                    Sugar. 
Blood pressure  :                                Blood  :  sugar. 
C.V.S.                                                              Urea. 
R.S.                                                    Serum :  creatinine. 
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E.C.G.                                                              electrolytes. 
Chest-X- ray                                      Bleeding time. 
A.S.A:                                                Clotting   time. 
                                                            Platelet count: 
 
PREMEDICATION : 
 
Injection Atropine 20µgm/kg IM 60 minutes before surgery. 
 
INDUCTION OF   ANAESTHESIA: 
 
Injection Pentazocine 0.5mg/kg I.V. 
Pre-oxygenation 
Induction agent          Thiopentone – 5mg/kg I.V. 
Identification of supramaximal stimulus in mA. 
Relaxant for intubation     Atracurium 0.5mg/kg. 
Intubation. 
Relaxant for surgery         Atracurium 0.15mg/kg. 
Ventilation: Intermittent positive pressure ventilation. 
Halothane 0.5% used until the conclusion of surgery. 
Nitrous oxide /  oxygen  in  ratio  of  66 % / 33% used  for  maintenance  of 
anaesthesia . 
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OBSERVATIONS BEFORE ADMINISTRATION OF NEOSTIGMINE. 
 
 
Time of administration of loading dose of atracurium 0.5mg/kg: 
 
Time of administration of top-up dose of atracurium: 
 
 
1st 2nd 3rd 4rth 5th 6th 7th 8th 
        
 
 
 
OBSERVATIONS MADE AT THE TIME OF ADMINISTRATION OF 
NEOSTIGMINE & ATROPINE. 
 
Time of last dose 
Of atracurium 
given. 
TOF response at the 
time of 
administration of 
reversal agent . 
Heart rate. Blood 
pressure. 
Sbp/dbp. 
SpO2. 
     
 
 
OBSERVATIONS MADE AFTER ADMINISTRATION OF 
NEOSTIGMINE: 
 
Time req. for TOF 
response without 
fade 
Time req. for 
DBS  
without  fade 
Time req. for 
clinical 
Signs to be 
present. 
Time of 
extubation. 
    
 
HAEMODYNAMIC  AND  RESPIRATORY  PARAMETERS  AFTER  
EXTUBATION . 
 
PARAMETERS 5 10 15 20 25 30 35 40 45 50 55 60min 
 
Heart rate             
Blood pressure             
SpO2             
Resp.rate.             
 
ADVERSE EFFECTS: 
